Bigger bets on three growth drugs
Novartis sounded more upbeat on three of its key products while investors continue to ask how growth holds up after 2031 as older medicines lose exclusivity. The Swiss drugmaker raised its peak-sales view for multiple sclerosis therapy Kesimpta, leukemia drug Scemblix and cholesterol treatment Leqvio to a combined $18 billion from $14 billion.
CEO Vas Narasimhan said the boost is mainly about execution on the ground. "It's really that in-market commercial performance that's driving these upgrades," he told reporters on Thursday, citing rising share for Kesimpta and for Scemblix and strong uptake of Leqvio in the U.S. and Asia. A caption in the materials also places Narasimhan at a White House Roosevelt Room event on Dec. 19, 2025.
Guidance tweak and the Kisqali cliff
Even with stronger expectations for those three drugs, the broader outlook leaned a touch more cautious. Novartis now guides to 5% a year through 2031, compared with its prior 5% to 6% through 2030, noting the new figure spans a different five-year period.
Narasimhan said the revision accounts for an expected U.S. generic entry for the breast cancer medicine Kisqali in the latter half of 2031. According to Citi, the 2031 sales guide is roughly 3% ahead of consensus, and the firm added that investors are likely to stay doubtful about post-2031 growth until more pipeline data are available.
When companies update forecasts, staying informed matters, so sign up for the free Market Briefs to get clarity
Trial stumbles and the case for the strategy
Recent R&D news has been rough. In September, the closely watched pelacarsen study did not show improved cardiovascular outcomes, and the next day the del-desiran program failed in a late-stage trial, sending the stock down nearly 11% in its worst one-day drop since 1987.
Narasimhan defended how Novartis deploys capital, noting del-desiran came with a $12 billion acquisition of Avidity Biosciences earlier this year. He said shareholders hold differing views on dealmaking, but he highlighted a total shareholder return of 275% across the last decade and said it ranks among the sector's best.
What it means for your portfolio
Here is the setup: three growth drivers now aim higher, while the company's long-run pace assumes a 2031 generic hit to Kisqali and leaves the post-2031 arc an open question. Citi's read underscores the same tension - guidance ahead of consensus today, but investors will want more pipeline proof for the years beyond. For positioning, watch whether Kesimpta, Scemblix and Leqvio keep compounding toward that $18 billion target and how the timeline around Kisqali's U.S. competition evolves, alongside the delayed-quote snapshot that showed 127.82, down 3.66 or 2.78% at 3:25 PM CET.
Because understanding economic context helps make sense of company news, subscribe to Market Briefs newsletter for five minutes a day
